Abstract:For the majority of pediatric patients with soft tissue tumors, some form of selective systemic therapy is required. Here we show that bone marrow-derived non-hematopoietic mesenchymal stem cells (MSCs) integrate into pediatrics soft tissue sarcoma xenografts as stromal fibroblasts. Importantly, exogenously administered MSC preferentially engraft at the sites of disseminated tumor nodules throughout the body. These findings suggest the development of novel anti-cancer therapies based on the local production of biological agents by gene manipulated MSC. We show that human MSC can be effectively transduced with adenovirus type 5-based vectors and with vectors based on adeno-associated virus (AAV). The majority of AAV serotypes tested (AAV1/6, 2, 3, 4, 5, and 8) are capable of transducing hMSC, albeit with relatively low efficiencies. Vector modifications to the AAV capsid, such as the inclusion of the RGD-tripeptide motif in capsids of either AAV1 or AAV2-based vectors, or modification of the vector genome to generate "double-stranded", or "self-complementary" AAV vectors, both lead to significant increases in AAV-mediated hMSC gene transduction. Here, we examined whether hMSC producing human TNF-related apoptosis inducing ligand (hTRAIL) (hTRAIL-MSC) can inhibit the growth of subcutaneous human Ewing's Sarcoma xenografts in nude mice. MSC were transduced with an hTRAIL expressing adenovirus, or AAV vector. These hTRAIL-MSC produced hTRAIL and could directly induce apoptosis of A673 Ewing's sarcoma cells in co-culture experiments in vitro. When co-injected with A673 sarcoma cells into the flanks of nude mice (1:2 ratio of hMSC to A673 sarcoma cells), all treated animals failed to develop tumors (n=5). Control animals co-injected with eGFP-MSC (Ad-eGFP transduced hMSC) and A673 sarcoma cells (n=5), or A673 sarcoma cells alone (n=10) all developed tumors. We then injected hTRAIL-MSC intravenously (IV) (single dose of 5 105 MSC) into nude mice bearing established subcutaneous A673 tumors; tumor growth was inhibited approximately 30% as compared to untreated controls, and as compared to controls treated with eGFP-MSC (n=5) (p=0.01). Immunohistochemical analysis of hTRAIL-MSC treated animals showed engraftment and differentiation of hMSC into myofibroblast-like tumor-associated stroma cells. IV injected hTRAIL-MSC prolonged the survival of mice bearing A673 Ewing sarcoma grafts as compared to untreated animals, or control (eGFP-MSC) treated animals. These data suggest that IV administered gene-modified MSC can inhibit the growth of pediatric soft tissue sarcomas. Importantly, the antitumor effects were only achieved when MSC were integrated into the tumor microenvironment, but not when MSC were injected subcutaneously into the opposite flank. Therefore, tumor inhibition required spatial proximity of MSC to the malignant cells. These findings suggest that TRAIL can serve as a direct inhibitor of tumor proliferation and suggest the use of gene-manipulated MSC for pediatric cancer therapy.

Trail-Expressing Gingival-Derived Mesenchymal Stem Cells Inhibit Tumorigenesis of Tongue Squamous Cell Carcinoma

Human Menstrual Blood-Derived Mesenchymal Stem Cells As a Cellular Vehicle for Malignant Glioma Gene Therapy

Human Bone Marrow-Derived Mesenchymal Stromal Cells Expressing S-TRAIL as a Cellular Delivery Vehicle for Human Glioma Therapy

The Growth Inhibitory Effect of Human Gingiva-Derived Mesenchymal Stromal Cells Expressing Interferon-Β on Tongue Squamous Cell Carcinoma Cells and Xenograft Model.

Site-Specific Integration of TRAIL in Ipsc-Derived Mesenchymal Stem Cells for Targeted Cancer Therapy

Mesenchymal Stem Cells As Therapeutic Agents and in Gene Delivery for the Treatment of Glioma

74. Specific Delivery of hTRAIL and Inhibition of Ewing's Sarcoma Growth by Transplantation of Viral Vector-Transduced Bone Marrow-Derived Mesenchymal Stem Cells (MSC)

The inhibitory effect of MSCs expressing TRAIL as a cellular delivery vehicle in combination with cisplatin on hepatocellular carcinoma.

IFN-γ-secreting-mesenchymal stem cells exert an antitumor effect in vivo via the TRAIL pathway.

Mesenchymal Stem Cells As a Novel Carrier for Targeted Delivery of Gene in Cancer Therapy Based on Nonviral Transfection.

Mesenchymal Stem Cells Derived from Normal Gingival Tissue Inhibit the Proliferation of Oral Cancer Cells in Vitro and in Vivo.

Suppression of orthotopically implanted hepatocarcinoma in mice by umbilical cord-derived mesenchymal stem cells with sTRAIL gene expression driven by AFP promoter

Lentivirus-mediated Gene Transfer of Human Strail Induced Apoptosis in SGC-7901 Cells

Chemotaxis of Bone Marrow-Derived Mesenchymal Stem Cells to Gastric Cancer Cells in Vivo and in Vitro

In Vivo Tracking of the Tropism of Mesenchymal Stem Cells to Malignant Gliomas Using Reporter Gene-Based MR Imaging

Mesenchymal Stem Cell‐derived CCN2 Promotes the Proliferation, Migration and Invasion of Human Tongue Squamous Cell Carcinoma Cells

Human Umbilical Cord Mesenchymal Stem Cells Delivering Strail Home to Lung Cancer Mediated by MCP-1/CCR2 Axis and Exhibit Antitumor Effects

Nanoscale biomimetic nano system for the co-delivery of SNS032 and tumor necrosis factor related apoptosis inducing ligand to enhance therapeutic efficacy in oral squamous cell carcinoma cell line SCC25

Antitumor Effect of TRAIL on Oral Squamous Cell Carcinoma using Magnetic Nanoparticle-Mediated Gene Expression

Use of Genetically Engineered Bone Marrow-Derived Mesenchymal Stem Cells for Glioma Gene Therapy

The Experimental Investigation of Glioma ⁃trophic Capacity of Human Umbilical Cord-Derived Mesenchymal Stem Cells after Intraventricular Administration